Abstract
We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1-2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59-87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.
Publication types
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Boronic Acids / adverse effects
-
Boronic Acids / therapeutic use*
-
Bortezomib
-
Combined Modality Therapy
-
Fatigue / etiology
-
Female
-
Follow-Up Studies
-
Graft vs Host Disease / epidemiology
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / prevention & control*
-
Hematopoietic Stem Cell Transplantation* / adverse effects
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / surgery
-
Peripheral Nervous System Diseases / etiology
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / therapeutic use*
-
Pyrazines / adverse effects
-
Pyrazines / therapeutic use*
-
Retrospective Studies
-
Salvage Therapy*
-
Survival Analysis
-
Thrombocytopenia / etiology
-
Transplantation Conditioning / adverse effects
-
Transplantation Conditioning / methods*
-
Transplantation, Homologous / adverse effects
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Protease Inhibitors
-
Pyrazines
-
Bortezomib